Proteoglycan mimetics for enhanced wound healing, angiogenesis, and vascular repair

Patent metadata

Field	Value
Publication number	US-11612663-B2
Application number	US-202017062300-A
Country	US
Kind code	B2
Filing date	Oct 2, 2020
Priority date	Apr 5, 2018
Publication date	Mar 28, 2023
Grant date	Mar 28, 2023

Abstract

The present disclosure provides pro-angiogenic proteoglycan mimetics that can provide a provisional, pro-angiogenic scaffold to support tissue regeneration while limiting systemic exposure to VEGF activity. These mimetics can protect a collagen matrix from rapid degradation, and in conjunction with EPCs promote angiogenesis in order to accelerate ischemic wound healing. For example, the provided compounds can be delivered from the end of a catheter following balloon angioplasty to coat the collagen exposed areas, prevent platelet binding and thrombosis, support capture of EPCs from blood to facilitate reendothelialization, and reduce late-lumen loss (neointimal hyperplasia).

First claim

What is claimed is:

1. A compound comprising:
one or more P1 subunits, wherein P1 is a synthetic peptide comprising an amino acid sequence that comprises a collagen-binding domain having the amino acid sequence RRANAALKAGELYKSILY (SEQ ID NO: 1) or a conservatively modified variant sequence having at least 80% sequence identity with the amino acid sequence RRANAALKAGELYKSILY (SEQ ID NO: 1);
one or more P2 subunits, wherein P2 is a synthetic peptide comprising an amino acid sequence that comprises an integrin-binding domain, and wherein P2 is selected from the group consisting of cGRGDdvc (LXW7), cGRGDsfc, cGRGDdfc, cGRGDsec, cGRGDdsc, cGRGDd-DBug-c, cGRGDd-DBta-c, Ac-cGRGDdvc, (β-alanine)-cGRGDdvc, (Ebes)-cGRGDdvc, cGRGDd-DAgl-c, cGRGDd-DPra-c, cGRGDd-D(NMe)Val-c, cGRGDd-D(CαMe)Val-c, cGRGDd-DAbu-c, cGRGDd-DNal1-c, cGRGDd-DNal2-c, and peg2V; and
a glycan, wherein each P1 subunit and each P2 subunit is linked to the glycan.

2. The compound of claim 1 , wherein P1 is a synthetic peptide comprising the amino acid sequence RRANAALKAGELYKSILY (SEQ ID NO: 1).

3. The compound of claim 1 , wherein P1 is a synthetic peptide of up to 40 amino acids comprising the amino acid sequence RRANAALKAGELYKSILY (SEQ ID NO: 1).

4. The compound of claim 1 , wherein P2 is a synthetic peptide comprising an amino acid sequence that comprises an αvβ3-binding domain.

5. The compound of claim 1 , wherein P2 is LXW7.

6. The compound of claim 1 , wherein P2 is peg2V.

7. The compound of claim 1 , wherein the glycan is a glycosaminoglycan or polysaccharide.

8. The compound of claim 7 , wherein the glycan is selected from the group consisting of alginate, agarose, dextran, chondroitin, dermatan, dermatan sulfate, heparan, heparin, keratin, and hyaluronan.

9. The compound of claim 8 , wherein the glycan is selected from the group consisting of dermatan sulfate, dextran, and heparin.

10. A compound comprising:
one or more P1 subunits, wherein P1 is a synthetic peptide comprising an amino acid sequence that comprises a collagen-binding domain having the amino acid sequence RRANAALKAGELYKSILY (SEQ ID NO: 1) or a conservatively modified variant sequence having at least 80% sequence identity with the amino acid sequence RRANAALKAGELYKSILY (SEQ ID NO: 1); and
one or more P2 subunits, wherein P2 is a synthetic peptide comprising an amino acid sequence that comprises an integrin-binding domain, and wherein P2 is selected from the group consisting of cGRGDdvc (LXW7), cGRGDsfc, cGRGDdfc, cGRGDsec, cGRGDdsc, cGRGDd-DBug-c, cGRGDd-DBta-c, Ac-cGRGDdvc, (β-alanine)-cGRGDdvc, (Ebes)-cGRGDdvc, cGRGDd-DAgl-c, cGRGDd-DPra-c, cGRGDd-D(NMe)Val-c, cGRGDd-D(CαMe)Val-c, cGRGDd-DAbu-c, cGRGDd-DNal1-c, cGRGDd-DNal2-c, and peg2V.

11. The compound of claim 10 , wherein P1 is a synthetic peptide comprising the amino acid sequence RRANAALKAGELYKSILY (SEQ ID NO: 1).

12. The compound of claim 10 , wherein P1 is a synthetic peptide of up to 40 amino acids comprising the amino acid sequence RRANAALKAGELYKSILY (SEQ ID NO: 1).

13. The compound of claim 10 , wherein P2 is a synthetic peptide comprising an amino acid sequence that comprises an αvβ3-binding domain.

14. The compound of claim 10 , wherein P2 is LXW7.

15. A composition comprising the compound of claim 1 and one or more pharmaceutically acceptable excipients, diluents, or a combination thereof.

16. A method for improving endothelialization and vascularization of endothelial cells and/or endothelial progenitor cells in a subject, the method comprising administering to the subject a composition comprising the compound of claim 1 .

17. The method of claim 16 , wherein the composition comprises one or more pharmaceutically acceptable excipients, diluents, or a combination thereof.

Assignees

• Univ California
• Purdue Research Foundation

Inventors

• Panitch Alyssa
• Misnick Emily Michelle
• Lin Jenny B
• Lam Kit S
• Liu Ruiwu
• Hao Dake
• Wang Aijun

Classifications

• A61P9/14

  Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers · CPC title

• A61K38/10 Primary

  Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)} · CPC title

• A61K47/64

  Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) · CPC title

• A61K47/61 Primary

  the organic macromolecular compound being a polysaccharide or a derivative thereof · CPC title

• C07K7/08

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title